Serum Institute of India (SII) CEO Adar Poonawala said on Saturday that the clinical trial of Kovid-19 vaccine Kovovax has begun in India. He hoped that this vaccine could be introduced by September this year.
In August 2020, the US vaccine company Novavax Inc. announced a license agreement with SII. Novavax has signed this agreement for the development and commercialization of its Kovid-19 vaccine ‘Candidate NVX-CO 2373’. The vaccine will be made available to India and countries in the lower and middle income groups.
Poonawala tweeted, “Trial of Kovovax has begun in India. The vaccine is being developed in partnership with Novavax and Serum Institute. This vaccine has been tested against Kovid-19 variants in Africa and the UK. Its overall efficiency is found to be 89 percent. We hope that this vaccine can be introduced by September 2021. ”
However, the commercial deal between Novavax and SII does not include high-middle and high-income countries. Novavax has the right to the vaccine for these countries. Poonawala said in January this year that SII expects Kovovax to be rolled out by June 2021. SII is already supplying the Kovid-19TK ‘Kovishield of AstraZeneca / Oxford to India and many countries of the world.